<DOC>
	<DOC>NCT00969527</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy of Oncoxin+Viusid administration in the treatment of rheumatoid arthritis. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons with rheumatoid arthritis to be recruited and randomized for the study is 86. The primary outcome measure: DAS28 score will be assessed at the end of the study.</brief_summary>
	<brief_title>Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Treatmentnaive subjects with recent onset rheumatoid arthritis Signed informed consent Subjects with rheumatoid arthritis symptoms other than those associated with joints at disease onset Subjects with joint function impairment secondary to other conditions not associated with rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Oncoxin</keyword>
	<keyword>Viusid</keyword>
	<keyword>dietary supplements</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>